Ubs Asset Management Americas Inc Atara Biotherapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.8 - $5.46 $302,411 - $589,701	108,004 New	108,004 $313,000
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $69,722 - $139,528	8,261 Added 11.28%	81,523 $757,000
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $779 - $1,054	53 Added 0.07%	73,262 $1.15 Million
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $154,706 - $230,963	-12,903 Reduced 14.98%	73,209 $1.31 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $68,239 - $87,774	5,294 Added 6.55%	86,112 $1.34 Million
Q4 2020 Mar 01, 2021	BUY	$12.67 - $26.23 $257,644 - $533,387	20,335 Added 33.62%	80,818 $1.59 Million
Q3 2020 Nov 13, 2020	SELL	$11.92 - $15.87 $55,964 - $74,509	-4,695 Reduced 7.2%	60,483 $783,000
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $45,292 - $89,803	6,015 Added 10.17%	65,178 $949,000
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $80,536 - $251,658	14,154 Added 31.45%	59,163 $503,000
Q4 2019 Feb 14, 2020	SELL	$10.89 - $16.79 $3.41 Million - $5.25 Million	-312,841 Reduced 87.42%	45,009 $741,000
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $1.08 Million - $1.8 Million	90,077 Added 33.64%	357,850 $5.05 Million
Q2 2019 Aug 15, 2019	BUY	$19.05 - $41.04 $777,163 - $1.67 Million	40,796 Added 17.97%	267,773 $0
Q1 2019 May 14, 2019	BUY	$28.4 - $41.74 $25,560 - $37,566	900 Added 0.4%	226,977 $0
Q4 2018 Feb 13, 2019	BUY	$30.9 - $42.97 $267,563 - $372,077	8,659 Added 3.98%	226,077 $7.85 Million
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $534,091 - $662,853	-15,238 Reduced 6.55%	217,418 $0
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $7.64 Million - $11.2 Million	217,362 Added 1421.22%	232,656 $0
Q1 2018 May 14, 2018	BUY	$18.0 - $48.35 $275,292 - $739,464	15,294 New	15,294 $0

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account